Cargando…

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations

BACKGROUND: Neoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Study of Lung Cancer (IASLC) published recommendation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muñoz-Guglielmetti, Diego, Sanchez-Lorente, David, Reyes, Roxana, Martinez, Daniel, Lucena, Carmen, Boada, Marc, Paredes, Pilar, Parera-Roig, Marta, Vollmer, Ivan, Mases, Joel, Martin-Deleon, Roberto, Castillo, Sergi, Benegas, Mariana, Muñoz, Silvia, Mayoral, Maria, Cases, Carla, Mollà, Meritxell, Casas, Francesc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641007/ https://www.ncbi.nlm.nih.gov/pubmed/34909399 http://dx.doi.org/10.5306/wjco.v12.i11.1047

Ejemplares similares

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

Clinical outcomes and timing on the combination of focal radiation therapy and immunotherapy for the treatment of brain metastases
por: Antelo, Gabriela, et al.
Publicado: (2023)

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
por: Aya, Francisco, et al.
Publicado: (2021)

IASLC Textbook of Prevention and Early Detection of Lung Cancer
por: Spiro, S G
Publicado: (2006)

Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma
por: Zabeck, Heike, et al.
Publicado: (2018)

Intraoperative electron radiation therapy after salvage surgery in gynecological cancers and retroperitoneal sarcomas: outcomes and adverse effects
por: Oses, Gabriela, et al.
Publicado: (2022)

Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee
por: Pass, Harvey I., et al.
Publicado: (2014)

A Simplified Version of the IASLC Grading System for Invasive Pulmonary Adenocarcinomas With Improved Prognosis Discrimination
por: Bossé, Yohan, et al.
Publicado: (2023)

The IASLC grading system for invasive pulmonary adenocarcinoma: a potential prognosticator for patients receiving neoadjuvant therapy
por: E, Haoran, et al.
Publicado: (2023)

A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma
por: Wang, Kai, et al.
Publicado: (2023)

Saddle Pulmonary Embolism in Patients with Cancer in the Era of Incidental Events: Clinical Findings and Outcomes in a Single Centre Cohort
por: Aramberri, Mario, et al.
Publicado: (2022)

Saddle Pulmonary Embolism in Patients with Cancer in the Era of Incidental Events: Clinical Findings and Outcomes in a Single Centre Cohort
por: Aramberri, Mario, et al.
Publicado: (2022)

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”
por: Vigneswaran, Wickii T., et al.
Publicado: (2020)

Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations
por: Jarabo Sarceda, José Ramón, et al.
Publicado: (2021)

Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma
por: Wang, Hongyan, et al.
Publicado: (2018)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Cancer stem cell-related marker expression in lung adenocarcinoma and relevance of histologic subtypes based on IASLC/ATS/ERS classification
por: Shimada, Yoshihisa, et al.
Publicado: (2013)

New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma
por: Weng, Ching-Fu, et al.
Publicado: (2020)

Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification
por: Boukansa, Sara, et al.
Publicado: (2022)

Is invasive mediastinal staging necessary in intermediate risk patients with negative PET/CT?
por: Boada, Marc, et al.
Publicado: (2020)

Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma
por: Sun, Yifeng, et al.
Publicado: (2016)

肺腺癌IASLC/ATS/ERS国际多学科分类以及临床实践中应注意的问题
Publicado: (2013)

Validation of the Proposed cN2 Subclassification in the Eighth Edition of the IASLC Staging System: A Prospective Phase II Multicenter Study
por: Abe, Jiro, et al.
Publicado: (2020)

A predictive nomogram for lymph node metastasis in part-solid invasive lung adenocarcinoma: A complement to the IASLC novel grading system
por: Gao, Zhaoming, et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC
por: MacManus, Michael, et al.
Publicado: (2023)

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients
por: Marin, Elba, et al.
Publicado: (2020)

Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients
por: Wang, Tengteng, et al.
Publicado: (2017)

PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
por: Smeltzer, M., et al.
Publicado: (2021)

A Proposal to Modify the 8th IASLC System: Is it Suitable for T4N2M0 Lung Adenocarcinoma to Be Placed in Stage IIIB?
por: Ruan, Tian, et al.
Publicado: (2022)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
por: Molla, Meritxell, et al.
Publicado: (2021)

Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea
por: Woo, Wongi, et al.
Publicado: (2022)

Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
por: Yaprak, Gokhan, et al.
Publicado: (2019)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uebvaaq07ttnqkjjtjs1selp5f